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Objective: Our aim was to explore the engendering mechanism and gene targets for melanoma.
Methods: The microarray data of GSE46517 were downloaded from the Gene Expression Omnibus
database. The differentially expressed genes (DEGs) between primary melanoma samples and normal
controls were analyzed using the GEO2R online tool. The screened DEGs were mapped to a protein
eprotein interaction network based on the Search Tool for the Retrieval of Interacting Genes database.
The functions and pathways involved with DEGs were analyzed using the Database for Annotation
Visualization and Integrated Discovery software) online tools. Then, the DEGs were further annotated via
the TRANSFAC, Tumor-Suppressor Gene, and Tumor-Associated Gene databases.
Results: A total of 1095 DEGs including 511 upregulated genes and 584 down-regulated ones were
screened out. The nodes of CCL5, ISG15, CDKN2A, EGFR, and ERBB2 showed a high connectivity degree in
proteineprotein interaction networks and were mainly enriched in Biological Process GO terms such as
the regulation of catalytic activity and cell adhesion, as well as the pathways of cytochrome P450. The
DEGs were classiﬁed into 31 transcription factors and 43 downregulated tumor associated genes.
Conclusion: Catalytic activity, cell adhesion, and the cytochrome P450 associated pathways are dysre-
gulated in the melanoma formation. The signiﬁcant nodes such as ISG15, IRF4, ERBB2 and EGFP may be
potential targets for primary melanoma treatment.
Copyright © 2015, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Melanoma is a type of skin cancer characterized by the neoplasm
development of pigment-producing cells called melanocytes.
Melanoma is common in the skin, but may also develop in the eyes,
ears, gastrointestinal tract, leptomeninges, oral and genital mucous
membranes.1 Melanoma is among the most rapidly increasing
cancers of the white population in the USA.2 It is estimated that
61,300 new cases are expected to be diagnosed in 2013.3 Melanoma
has metastatic potential and the median survival for metastatic
melanoma patients is only 6e9months.4 Melanoma poses a burdeny have no ﬁnancial or non-
atter or materials discussed
ery, First Afﬁliated Hospital of
ical Association. Published by Els
.to public health. A good understanding of genetic events underly-
ing melanoma development can lead to the success of targeted
therapies in melanoma treatment.5 Melanoma pathogenesis has
been proved to be driven by genetic mutation. Curtin et al6 indi-
cated that the mutations of BRAF or NRAS are common in the ma-
jority of melanomas without chronic sun-induced damage in skin.
Reports showed that MITF, CCND1, BRAF, CDKN2A, and PTEN are
some of the validated oncogenes and tumor suppressors selectively
targeted by focal copy number-changing aberrations in mel-
anoma.7e9 Furthermore, microarray technology has been applied
for investigating gene expression patterns for melanoma. Lawrence
et al10 developed microarray data of GSE46517 and proposed that
chromosome 10, which encodes multiple tumor-suppressive
functions, is frequently lost in human melanoma.10 With the
microarray data of GSE8041 and GSE46517, McCorkle et al11 found
that NME1 regulated the expression of genes that related with the
metastasis and outcomes of patients with melanoma. However, the
systematic studies of the aberrant gene expression of melanomaevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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remains unclear.
Therefore, in the present study, we downloaded the publicly
available microarray data (GSE46517) from the Gene Expression
Omnibus (GEO) database and performed comprehensive analysis of
gene expression patterns. The aim of this current work was to
explore the potential molecular mechanism of melanoma and un-
cover the candidate gene targets for melanoma treatment.Methods
Gene expression proﬁles
The publically available dataset (accession number: GSE46517)
were downloaded from the GEO database (http://www.ncbi.nlm.
nih.gov/geo/).12 The expression proﬁles data were developed from
121 samples, including 73 metastatic melanoma samples, 31 pri-
mary melanoma samples, one epithelial melanocyte sample, and
seven normal skin samples. In the present work, the data from the
31 primary melanoma samples and seven normal skin samples
were selected for further analysis based on the Affymetrix Human
Genome U133A 2.0 Array (HG-U133A_2) platform.Differentially expressed gene screening
The differentially expressed genes (DEGs) between primary mela-
noma and the normal controls were analyzed using the web tool
GEO2R (https://www.ncbi.nlm.nih.gov/geo/info/geo2r.html). Dif-
ferences in gene expression values were evaluated by t test. Mul-
tiple testing correction was performed using the
BenjaminieHochberg method.13 Finally, the DEGs with t (log2 fold
change) >1 and adjusted p < 0.05 were screened.Proteineprotein interaction network construction
The Search Tool for the Retrieval of Interacting Genes (STRING)
database is a collection of protein interaction data. It provides
function and scores for protein pairs.14 The protein interaction pairs
of the screened DEGs were analyzed via the STRING database.
Protein pairs with required conﬁdence (combined score) >0.9 were
screened for proteineprotein interaction (PPI) network construc-
tion. The network was visualized by Cytoscape software.15 The hub
nodes in the PPI network were then identiﬁed based on the con-
nectivity degree (number of neighbors) in the network statistics
according to the scale-free attribute.16Functions and pathways enrichment of DEGs
The Gene Ontology (GO) database is an open source for function
annotation of a scale of genes.17 The Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway database is a collection of various
biochemical pathways.18 The signiﬁcantly overrepresented GO
terms in biological process (BP) and pathways of DEGs were
analyzed using the database for annotation, visualization and in-
tegrated discovery.19 A p value < 0.05 was set as cut-off criterion.Table 1 The numbers of the upregulated and downregulated probes and differen-
tially expressed genes.
Probe counts Gene counts
Upregulated 607 511
Downregulated 742 584
Total 1349 1095
Probe counts ¼ number of probes with query signal; Gene counts ¼ number of
differentially expressed genes.Gene function annotation
The potential transfer factors (TFs) among DEGs were screened
based on the TRANSFAC database.20 The oncogenes and anti-
oncogenes of the DEGs were determined based on the Tumor-
Suppressor Gene (TSGene)21 and Tumor-Associated Gene (TAG)
databases according to the method described by Chen et al.22Results
DEG screening
A total of 1095 genes corresponding to 1349 probes were identiﬁed
to be differentially expressed, which included 511 upregulated
DEGs and 584 downregulated genes. The detailed information is
listed in Table 1.
PPI network
The PPI networks for upregulated and downregulated DEGs were
constructed respectively. The PPI network for upregulated genes
contained 146 nodes and 278 edges (Figure 1A). As shown in
Figure 1B, there were 194 nodes and 265 edges in the PPI network
for downregulated genes. After the connectivity degree analysis,
the top 20 nodes with high degrees for the up- and downregulated
PPI network were screened (Table 2). The connectivity degrees of
the Top 20 nodes in the upregulated and downregulated PPI were
all higher than 6.
Functions and pathways enrichment analysis of DEGs
To explore the functions of the DEGs, the 511 upregulated and 584
downregulated genes were subjected to GO-BP and KEGG pathway
enrichment analysis. As shown in Table 3, the signiﬁcantly enriched
GO terms for upregulated genes were mainly related with the
regulation of catalytic activity (GO:0050790), innate immune
response (GO:0045087), chemotaxis (GO:0006935), and the regu-
lation of immune response (GO:0050776). The downregulated
genes were mainly enriched in cell adhesion (GO:0007155),
response to wounding (GO:0009611), the positive regulation of
gene expression (GO:0010628), and the enzyme linked receptor
protein signaling pathway (GO:0007167). KEGG pathway analysis
(Table 4) showed that upregulated genes were mainly enriched in
the chemokine signaling pathway (04062), the pathways in cancer
(05200), and the cytokineecytokine receptor interaction (04060).
The signiﬁcantly enriched pathways of downregulated genes were
metabolic pathways (01100) and focal adhesion (04510). Notably,
pathways of drug metabolismecytochrome P450 and metabolism
of xenobiotics by cytochrome P450 were enriched by the down-
regulated DEGs.
Functional annotations of DEGs
In order to analyze the aberrant gene expression pattern for TFs and
TAGs in primary melanoma, further functional analysis and anno-
tation for DEGs were performed. As shown in Table 5, 12 upregu-
lated DEGs (such as MITF, CDK2, STAT1, IRF4, and IRF7) were
identiﬁed to be TFs and 19 downregulated DEGs that determined to
be TFs included EGR3, SMARCA2, TBX3, VDR, and RXRA. Furthermore,
based on the TAG database, 20 upregulated DEGs were identiﬁed to
be well-documented TAGs, of which CCND2, CEP55, FOSL1, and IRF4
were oncogenes, and MMP11, CDKN2A, LPL, EIF2AK2, MAD1L1,
Figure 1 (A) Proteineprotein interaction (PPI) network of the upregulated differentially expressed genes (DEGs). (B) PPI network of the downregulated DEGs. The interaction pairs
of the screened DEGs were analyzed via the Search Tool for the Retrieval of Interacting Genes software. The PPI pairs were identiﬁed with the required conﬁdence (combined score)
>0.9 as a threshold, and the PPI network of these connections were constructed using Cytoscape software.
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downregulated DEGs were identiﬁed to be TAGs, of which six genes
(VAV3, RUNX1T1, BCL6, NCOA3, ERBB2, EGFR)were oncogenes and 18
genes (PTPRF, TGFBI, SMARCA2, RECK, IGFBP5, GAS1, LOX, TIMP3,
ARHGAP29, PTPN3, ZBTB16, CLU, KLF5, CTNND1,MUC1, EFNA1, BMP2,TPM1) were TSGenes. However, the functions of the remaining nine
DEGs (including the upregulated genes BAX, PAX5, CSPG4, NR4A2,
PAX3, CDK2, and OAS1 as well as the downregulated genes MAF,
MGP, TFAP2C, KLF4, ITGB4, SHH, TIAM1, CD44, and CYP3A4)were not
clear.
Table 2 Top 20 nodes with higher connectivity degrees in the proteineprotein interaction network of the upregulated and downregulated differentially expressed genes.
Category Gene Degree Gene Degree Gene Degree Gene Degree
Up ISG15 16 OAS1 13 IFI6 11 CXCL11 10
Up IRF7 15 MX1 13 CCR7 11 IRF4 10
Up IFIT1 15 CCL5 12 ISG20 11 CXCL10 10
Up OAS2 14 CXCL9 12 MX2 11 ICAM1 10
Up IL6 14 CXCL13 11 IFITM1 10 IFI27 10
Down CYP2E1 13 TPM1 9 GSTTP1 7 COL17A1 7
Down EGFR 13 ADH1B 8 ALDH2 7 BMP2 6
Down DCN 11 GSTA3 8 COL1A1 7 DMD 6
Down RXRA 10 TPM2 8 MAOA 7 TNNT1 6
Down ERBB2 10 VDR 7 MYH11 7 ALDH3A2 6
Down ¼ downregulated; Up ¼ upregulated.
Table 3 Top 10 enriched gene oncology functions in biological processes of the differentially expressed genes.
Category Term Description Count p
Up GO:0050790 Regulation of catalytic activity 37 3.33E-08
Up GO:0045087 Innate immune response 32 2.73E-12
Up GO:0006935 Chemotaxis 24 3.68E-09
Up GO:0050776 Regulation of immune response 24 1.34E-07
Up GO:0050900 Leukocyte migration 23 7.77E-16
Up GO:0009615 Response to virus 23 1.33E-15
Up GO:0008284 Positive regulation of cell proliferation 23 1.48E-07
Up GO:0030334 Regulation of cell migration 18 8.77E-08
Up GO:0042110 T cell activation 17 3.57E-08
Up GO:0045944 Positive regulation of transcription from RNA polymerase II promoter 17 0.000645
Down GO:0007155 Cell adhesion 41 6.65E-12
Down GO:0009611 Response to wounding 39 7.47E-09
Down GO:0010628 Positive regulation of gene expression 38 2.49E-08
Down GO:0007167 Enzyme linked receptor protein signaling pathway 37 3.15E-10
Down GO:0001568 Blood vessel development 30 2.58E-12
Down GO:0030198 Extracellular matrix organization 28 4.44E-16
Down GO:0071495 Cellular response to endogenous stimulus 26 8.29E-06
Down GO:0030334 Regulation of cell migration 25 1.05E-10
Down GO:0043588 Skin development 24 1.42E-12
Down GO:0008285 Negative regulation of cell proliferation 24 1.23E-07
Down ¼ downregulated; Up ¼ upregulated.
Table 4 Top 10 enriched pathways of the differentially expressed genes.
Category Term Description Count p
Up 4062 Chemokine signaling pathway 14 1.26E-06
Up 5200 Pathways in cancer 13 0.001729
Up 4060 Cytokine-cytokine receptor interaction 11 0.002921
Up 4620 Toll-like receptor signaling pathway 9 2.90E-05
Up 4514 Cell adhesion molecules 8 0.001136
Up 5160 Hepatitis C 8 0.001193
Up 4810 Regulation of actin cytoskeleton 8 0.019073
Up 4670 Leukocyte transendothelial migration 7 0.00229
Up 4650 Natural killer cell mediated cytotoxicity 7 0.005551
Up 5323 Rheumatoid arthritis 6 0.003041
Down 1100 Metabolic pathways 35 0.010549
Down 4510 Focal adhesion 13 0.0003
Down 5200 Pathways in cancer 12 0.043972
Down 982 Drug metabolism - cytochrome P450 11 3.05E-07
Down 980 Metabolism of xenobiotics by cytochrome P450 10 2.06E-06
Down 4020 Calcium signaling pathway 10 0.004269
Down 4810 Regulation of actin cytoskeleton 9 0.037219
Down 5414 Dilated cardiomyopathy 8 0.000607
Down 4270 Vascular smooth muscle contraction 8 0.003141
Down 4520 Adherens junction 7 0.000852
Down ¼ downregulated; Up ¼ upregulated.
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To gain insight into the engendering mechanism of the primary
melanoma, we systematically analyzed the gene expression proﬁleswith bioinformatics analysis. A total of 1095 DEGs including 511
upregulated and 584 downregulated were screened in the current
study. The biological functions of these DEGs were further explored
based on GO function and pathway enrichment data. Further
Table 5 Functional classiﬁcation on transcription factors (TFs) and tumor associated genes (TAGs) of the differentially expressed genes.
TF counts TF genes TAG counts TAG genes
Up 12 PAX5, RXRG, NR4A1, NR4A2, PAX3, LEF1,
MITF, SOX10, CDK2, STAT1, IRF4, IRF7
20 CCND2, CEP55, FOSL1, IRF4, MMP11, CDKN2A, LPL, EIF2AK2, MAD1L1,
NR4A1, SOD2, MAP4K1, ISG15, BAX, PAX5, CSPG4, NR4A2, PAX3, CDK2, OAS1
Down 19 EGR3, AR, RORA, SMARCA2, NFATC3, TBX3,
MAF, GATA3, IRF6, KLF4, TFAP2C, HDAC5, KLF5,
BCL6, NR3C1, NR2F6, VDR, RXRA, RARG
33 VAV3, RUNX1T1, BCL6, NCOA3, ERBB2, EGFR, PTPRF, TGFBI, SMARCA2, RECK,
IGFBP5, GAS1, LOX, TIMP3, ARHGAP29, PTPN3, ZBTB16, CLU, KLF5, CTNND1,
MUC1, EFNA1, BMP2, TPM1, MAF, MGP, TFAP2C, KLF4, ITGB4, SHH, TIAM1,
CD44, CYP3A4
Down ¼ downregulated; Up ¼ upregulated.
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documented TFs and TAGs, of which some were signiﬁcantly
involved in primary melanoma.
Our results showed that the GO term of regulation of catalytic
activity (GO:0050790) was most signiﬁcantly enriched by the
upregulated genes. It is reported that tyrosinase is responsible for
the melanin synthesis in skin, which results in the diversity of skin
color.23 The amount of melaninmade and deposited inmelanocytes
is determined by the catalytic activity of tyrosinase instead of the
abundance or tyrosinase gene activity. The tyrosinase, also known
as melanocyte-speciﬁc enzyme, is involved in the rate-limiting step
of themelanin synthesis pathway.24,25 One sign of the melanoma in
the early stage is the changes of shape and color of the existing
moles, which is owing to the production of dark pigment and
melanin by melanocytes.26 In the current study, the regulation of
catalytic activity was signiﬁcantly enriched by the upregulated
DEGs, suggesting that the catalytic activity was accelerated. This is
in agreement with the previous reports.
It was also found that the drug metabolismecytochrome P450
and metabolism of xenobiotics by cytochrome P450 pathways are
signiﬁcantly related to the downregulated DEGs in primary mela-
noma. The cytochromes P450 are known as key enzymes in cancer
formation that mediate the metabolic activation of numerous
precarcinogens.27 Thus, these types of enzymesmight play a similar
role in the formation of melanoma. P450s are also regarded as an
appropriate therapeutic target since they are expressed at higher
levels in the tumor cells than in the surrounding normal tissue,28
and they might be used in the treatment of primary melanoma.
Several DEGs with a high connectivity degree in the PPI network
were identiﬁed in this study, such as ISG15 (connectivity
degree ¼ 16), IRF4 (degree ¼ 10), EGFR (degree ¼ 13), and ERBB2
(degree ¼ 10). ISG15 and IRF4 were found to be signiﬁcantly
upregulated and have been demonstrated to be TAGs. ISG15
encoded by the ISG15 gene has a role in innate immunity and
functions as a cytokine in lymphocytes and monocytes.29 The cy-
tokines ISG15 are expressed at high magnitude in melanomas and
induce E-cadherin expression on dendritic cells (DCs).30 E-cadherin
expression on monocyte-derived DCs may potentially inﬂuence the
migratory of DCs. DC inﬁltration is closely related with the induc-
tion of antitumor immunity that is associated with the prolonged
survival and metastatic disease prevention.31e33 GO enrichment
analysis suggested that ISG15 was mainly involved in the immune
response and Type I interferon-mediated signaling pathway. Since
Type I interferons were expressed at a high level in melanomas,30 it
is no wonder that many interferon-induced proteins were screened
out as signiﬁcantly upregulated DEGs including IFI6, IFI27, IFIT1, and
IFITM1, as well as many interferon regulatory factors including IRF4
and IRF7. Notably, IRF4 was identiﬁed to be both a TF and a TAG
upregulated in primary melanoma, which was consistent with the
Duffy et al34 ﬁnding that IRF4 and nevus count represented a strong
gene-by-age interactionwith a strong tendency tomelanoma. Thus,
ISG15 and IRF4 play key roles in the progression of melanoma.
The gene EGFR encoding the epidermal growth-factor receptor
tyrosine kinase was a signiﬁcantly downregulated gene with thesecond highest connectivity degree in primary melanoma. Further
annotation showed EGFR was an oncogene that was enriched in
several signiﬁcant BP-GO terms such as cell adhesion, enzyme-
linked receptor protein signaling pathway, regulation of cell
migration, and skin development. Members of the EGFR family have
been reported to be overexpressed in skin cancer.35 The EGFR
phosphorylation induced by UV accelerated the development of
skin cancer. Although EGFR is reported to be involved in progression
and metastasis of a subset of melanomas,36 it is still uncertainwhat
role it plays in primary melanoma. In this paper, function and
pathway enrichment analysis showed that EGFR participates in the
cell adhesion process and the focal adhesion pathway. It was re-
ported that cell adhesion molecules belonging to the integrin,
cadherin, and immunoglobulin superfamilies are implicated in
tumor progression of cutaneous melanoma.37 Another report
showed that during melanoma formation, there is a shift from
Ecadherin expression to neural Ncadherin expression in melano-
cytes.38 Hence, EGFR as a key component of signal transduction in
focal adhesion may contribute to primary melanoma process by
altering the expression of cadherin.
ERBB2, another signiﬁcantly downregulated DEG was identiﬁed
as an oncogene and showed close association with EGFR in the PPI
network. ERBB2, also known as neu/HER-2, is another epidermal
growth factor. The gene ampliﬁcation and protein overexpression
of ERBB2 are associated with various human cancers such as me-
dulloblastoma39 and breast carcinomas.40 Some evidence shows
that the focal adhesion signaling pathway might participate in
ERBB2-induced tumorigenesis.41 Therefore, ERBB2 interacting with
EGFR may play a key role in focal adhesion signaling pathway in
primary melanoma.
Although our studies predicted signiﬁcant biological function,
pathways and genes involved in melanoma formation, further
experimental validation is warranted.Conclusion
In summary, regulation of catalytic activity and cell adhesion, as
well as the cytochrome P450 associated pathways may be crucial in
melanoma formation. The signiﬁcant nodes with high degrees such
as ISG15, IRF4, ERBB2, and EGFP play critical roles in the progression
of melanoma and give insight to the biomarker and target therapy
for primary melanoma. However, numerous studies should be
conducted to validate our ﬁndings.References
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